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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not 
complimentary and alternative medicines are safe and effective in improving symptoms of adult 
patients over the age of 18 with active Crohn disease. 
 
Study design: A review of three published, randomized controlled trials (RCTs), one published 
in 2010, and the second and third in 2014. All English language.  
Data source: All 3 RCT’s were found using PubMed.  
Outcomes measured: All three studies measured improvement of Crohn disease symptoms 
through the Crohn Disease Activity Index (CDAI), Hamilton’s Depression Scale (HAMD), the 
Inflammatory Bowel Disease Questionnaire (IBDQ) and the Partial Harvey Bradshaw Index 
(pHBI). 
Results: Patient reported improved health-related quality of life and gastrointestinal function 
Conclusions:  The studies demonstrate some evidence that Complimentary and Alternative 
Medicines may improve acute symptoms of Crohn disease and an increased quality of life. 
However, it is inconclusive whether these therapies actually provide long-term results in healing 
patients with chronic disease. 
Key words: “Crohn Disease” & “Complimentary Therapies” 
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Introduction 
Crohn Disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of 
the gastrointestinal (GI) tract from mouth to anus.1 IBD is comprised of CD and ulcerative colitis 
(UC). CD is a chronic, relapsing and remitting disease characterized characterized by chronic 
diarrhea, abdominal pain and weight loss. Complementary and alternative medicine (CAM) is a 
term used to describe health and wellness therapies that have typically not been part of 
conventional Western medicine. “Complementary” suggest therapies that are used in conjunction 
with conventional medicine. “Alternative” suggests therapies used in substitution to conventional 
medicine.2 This study evaluates the efficacy of CAMs in improving the symptoms associated 
with active CD. 
Collectively, it is estimated that 1 in 200 Americans live with IBD.3 The incidence is 
evenly divided between CD and UC in the US. Studies have extrapolated that the direct medical 
costs based on insurance claims for all patients treated for IBD estimated up to 28 billion dollars 
in 2014.6 These costs include hospitalizations, prescription drugs, over the counter medications, 
hospital and physician services. Between 2011-2013, health plans estimated to pay out costs of 
$18,637 per patient with CD.6 Considering that the most common presenting symptom of CD is 
abdominal pain, this disease remains to be a diagnostic challenge for many clinicians across the 
medical landscape.4 
With the increasing popularity and influence of eastern medicine on western medicine, 
patients have greater access to complimentary and alternative therapies. The trend of “natural” 
remedies or holistic medicine has a place in today’s advancing medicine for both the patient and 
the consumer. Some of the most popular internet searches for alternative therapies include 
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acupuncture, Ayurveda medicine, chiropractic care and biofeedback. The utilization of CAMs in 
clinical trials offer insight to their safety and efficacy in treating a myriad of conditions.  
There are many natural remedies to treating abdominal pain. However, CAM 
interventions used in studies to treat CD aim at targeting more symptoms of the disease. 
Examples include the herb Artemisia absinthium, commonly known as wormwood; it is best 
known as the main ingredient in the alcoholic drink, absinthe. Another is acupuncture, a therapy 
that inserts small needles into specific zones of the body in order to stimulate an immune 
response. Moxibustion, or dried mugwort, is traditional Chinese herb used to augment medical 
therapies to increase healing.5 Lastly, diet is not well understood in CD. Some foods have been 
linked to inflammation, which has a direct affect with symptoms of CD.6 
The exact cause of CD is unknown, however it is understood to be involve interacting 
factors such as genetics, immune system and our personal environments.6 The emotional impact 
from sudden flair ups to embarrassing GI symptoms increases stress levels, which can weaken 
immune systems. Like many disease states of dysfunctional immune systems, there is no cure; or 
one specific treatment that is effective in all patients. Treatment approach is highly complex. 
Biologic agents such as TNF inhibitors are one of the current emerging treatments for CD. They 
have been shown to induce and maintain clinical remission in patients with moderate to severe 
CD.6 The many side effects and the administration of these drugs make them less appealing to 
some patients.  
Objective 
The objective of this selective EBM review is to determine whether or not CAMs are safe 
and effective in improving symptoms of adult patients over the age of 18 with active CD. 
Methods 
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The criteria used as a basis to this study included participant population, interventions 
used, comparison analysis between control groups and measurable outcomes. This review 
focused on a population of participants over the age of 18 with active CD. The interventions used 
in all three RCT’s were different types of complimentary and alternative medicines. These 
interventions were analyzed in comparison to participants over the age of 18 with active CD 
utilizing a placebo specific to each respective study. The outcomes that are measured include 
improvement of gastrointestinal-related and general symptoms of CD, improvement in healing, 
and an increased quality of life.  
The intervention used in the study Krebs et al., included powdered wormwood capsules 
versus the control placebo.7 Bao et al., compared the study group of participants receiving a 
combination of acupuncture augmented with moxibustion, against a control group of participants 
receiving placebo “superficial” acupuncture and moxibustion.8  Interventions addressed in the 
Brotherton et al. study focused on patients consuming a high fiber, low refined carbohydrate 
diet, with specific daily consumption of whole wheat bran cereal. This was compared against a 
control group consuming a modified elimination diet.9  
Article search and selection for this selective EBM review was conducted through 
PubMed. The key words used in the search were “Crohn Disease” and “Complimentary 
Therapies”. The studies chosen were all published in peer-review journals between 2010 and 
2014. All 3 studies were written in English and selected based on the preceding criteria, being 
patient-oriented evidence, as well as the clinical relevance to my question. Statistical data 
reported to determine clinical importance included p-value, relative risk reduction (RRR), 
absolute risk reduction (ARR), and number needed to treat (NNT) 
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Table 1 Demographics & Characteristics of included studies 
Study Type # Pts Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Krebs 
et al., 
2010 
 
RCT 20 18-80 
years 
Between the age of 
18-80 
 
Prior CDAI score of 
at least 200 for 3 mo  
Participants  
receiving TNF-alpha 
inhibitors  
0 Powdered 
wormwood 
(Artemisia 
absinthium) 
750mg x3 qd 
Bao et 
al., 
2014 
 
RCT  92 18-80 
years 
Diagnosis of mild or 
moderate CD;  
Negative history of 
salicylic acid and/or 
prednisone (at a 
dose ≤ 15 mg) for at 
least 1 month, and 
immunosuppressant 
or used anti-TNF-α 
biological agents for 
3 months prior to 
enrollment. 
Pregnant or lactating, 
heart, brain, liver, 
kidney, or 
hematopoietic 
disease, mental 
illness, other severe 
diseases. 
15 Acupuncture 
and 
moxibustion 
 
Broth
erton 
et al., 
2014  
 
RCT 7 18-64 
years 
Diagnosed with CD 
via colonoscopy and 
biopsy. 
 
Aged 18 to 64 years 
 
pHBI score ≥3  
 
At least 4 weeks of 
stable 
pharmacologic 
therapy. 
 
Use of Biologics, 
diverticulitis, short 
bowel syndrome, 
clinically significant, 
penetrating or 
stricturing CD, 
Special dietary 
restrictions, any 
disorder that might 
interfere with the 
ability to follow 
detailed dietary 
instructions over 
time, pregnancy; 
cancer, uncontrolled 
kidney or CVD, 
pHBI score >9.  
decompensated liver 
disease.  
0 High fiber and 
low refined 
carbohydrate 
diet; including 
consumption 
of whole wheat 
bran cereal. 
 
Outcomes Measured 
The main outcome in the Krebs et al. study was the improvement of CD symptoms 
measured through the Crohn Disease Activity Index (CDAI).7 Participants were required to have 
a minimum CDAI score of at least 200 at baseline.7 This study also collected secondary 
outcomes of improved mood, measured by the Hamilton Depression Scale (HAMD) and serum 
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inflammatory markers.7 Outcomes measured in the Bao et al. study were also aimed at 
improvement of symptoms through CDAI.8 The study measured quality of life scores as 
secondary outcome through the Inflammatory Bowel Disease Questionnaire (IBDQ).8  The 
Brotherton et al. study addresses the effects of a high fiber diet on both the quality of life and 
gastrointestinal function of participants with CD.9 These effects were measured through IBDQ 
and the partial Harvey Bradshaw Index (pHBI).9 Systemic inflammation was measured in the 
blood as secondary outcome for this study. 
Results 
A total of 20 participants were enrolled in the Krebs et al. study with zero withdrawal 
during the 6-week trial.7 Ten participants were randomly selected and divided into the group 
receiving wormwood, and the remaining ten were instructed not to take any additional 
medications, as comparison.7 Participants who were being actively treated for CD with either 5-
aminosalicylates, azathioprine or steroids, were kept on a stable dosage prior to the start of the 
trial.7 This study excluded patients who were taking TNF inhibitors to avoid comparison from a 
pharmacologic prospective.7 There were no significant differences between each participant in 
regards to age, duration of disease, extra-intestinal manifestations, and current medications.7 
Participants in the wormwood group were instructed to take one 750mg capsule 
containing powdered wormwood three times daily for 6 weeks.7 A significant improvement was 
defined by the author as a decrease in CDAI score of 70 points or decrease in HAMD scores of 
50% from baseline.7  At the end of 6 weeks, CDAI scores for the wormwood group decreased by 
an average of 100 points, with remission of symptoms in 8 participants.7 Based on the outcomes 
measured, this was deemed a significant improvement as compared to a decrease of only 22 
points in the control group.7 Control also reports remission of 2 patients at the end of the 6 week 
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trial. 
Of the secondary outcomes measured, there were reported improvements in mood 
symptoms. Participants in the wormwood group showed a decrease in their HAMD scores by an 
average of 9.9 points, as compared to the placebo group with a decrease of 3.5 points.7 To 
scientifically measure the reduction in pro-inflammatory cytokines, TNF-a levels were drawn at 
baseline, 3 and 6 weeks.7 By the sixth week, serum levels reduced an average of 17.5pg/ml for 
wormwood, whereas only 2.6pg/ml for control.7 Based on all reported data in Krebs et al. study, 
the relative risk reduction (RRR) was 3%, the absolute risk reduction (ARR)was 60% and the 
numbers needed to treat (NNT) was 2.7 Table 2 and 2a summarizes the primary outcome and 
efficacy of treatment.  
Table 2: Krebs et al. primary outcome: improve symptoms of CD per CDAI scores.  
Table 2a: efficacy of wormwood treatment on CD symptoms 
 Wormwood Group (n=10) Control Group (n=10) 
Score Baseline 6 weeks Mean  Baseline 6 weeks Mean  
CDAI 275 ± 15 175 ± 12 100 282 ± 11 260 ± 14 22 
CER EER RRR ARR NNT 
20% 80% 3% 60% 2 
 
There were 92 participants between the ages of 18-80 enrolled in the 12 week Bao et al. 
study with 7 withdrawals before completion.8 Treatment versus placebo were divided between 
43 and 42 participants, respectively.8 Of those, 40 of the treatment group and 37 of the control 
group completed a follow-up study at week 24.8 There were no significant differences in 
participants in terms of baseline data.8 There were two adverse events reported in the study. One 
treatment participant reported pain, and one control participant reported burning.8 At the 
conclusion, there was a 13% loss to follow up of the subjects who entered the trial.8 
Based on the results, CDAI scores from both groups reduced by the end of 12 weeks and 
Pellerito, CAMs for Crohn Disease 
 
7 
scores remained low for the treatment group by the 24 week follow up.8 Clinical significance is 
determined by a decrease in 70 points on the CDAI scale. There was 83.7% improvement of 
symptoms for the treatment group and 40.5% for the control.8 Based on this reported data the 
RRR was 1.1%, the ARR was 41.3% and NNT was 2.8 While both groups reported increase in 
quality of life through their IBDQ scores, the treatment group score was statistically greater with 
a difference of p-value, P = 0.017.8 The study found statistical evidence (p <0.001) that treatment 
with acupuncture and moxibustion did improve symptoms of CD per CDAI scores. Table 3 
summarizes these results.  
Table 3: Bao et al. mean values of CDAI and IBDQ scores.  
Table 3a: Efficacy of acupuncture and moxibustion treatment on CD symptoms 
 Treatment Group (n=43) Control Group (n=42) 
Baseline 12 weeks 24 weeks Baseline 12 weeks 24 weeks 
CDAI  210.84 ± 48.03 -115.35 ± 55.05 -128.93 ± 64.46  201.04 ± 
57.13  
-35.68 ± 
46.91 
-14.32 ± 
52.09 
CER EER RRR ARR NNT 
40.5% 83.7% 1.1% 43.2% 2 
 
Seven participants between ages 18-64 years were enrolled into the Brotherton et al. 
study.9 The participants had active CD symptoms and treated as outpatient clinic setting.9 Four 
participants were instructed on the intervention diet, which consisted of high fiber, including 0.5 
cup of wheat bran cereal, and low refined carbohydrate diet.9 The remaining three participants in 
the control group were instructed on a modified elimination diet based on “problematic foods” as 
per the Crohn and Colitis Foundation of America. Examples included whole grains, dairy 
products, and spicy foods.10 Due to lack of variability in participant pool, only females were 
enrolled into the control group. There were no adverse events reported in the study.9 
The author reports quality of life of the patients through IBDQ scores, with the range 
from 32-224.9 IBDQ measures bowel symptoms, systemic symptoms, emotional function, and 
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social function. 9 Clinical significance is determined by a score of ≥32-points.9 Clinical remission 
has been set at ≥170 points.9 With a baseline mean of 158.3, the treatment group improved their 
scores by 44.25 points. The control group had a baseline of 157.7 and increased by 19 points.9 
The increase in treatment scores were statistically significant over control (p = 0.028). All 
patients enrolled achieved clinical remission based on the IBDQ scale.9 Based on this reported 
data the RRR was 0, the ARR was 100%, and NNT was 10. 9  
The pHBI scores measured general well-being, abdominal pain, and number of liquid 
stools per day.9 This particular study required baseline scores to range between 3-9.9 Improved 
GI function was statistically significant (p = 0.008) with all participants of the treatment group 
reporting scores of zero, and control group reported scores of three at the end of the 4 week trial.9 
Systemic inflammation was measured in the blood as secondary outcome for this study. This 
data was dismissed due to lab mishandling. After the 4 weeks, there were no significant 
differences reported in CRP (p-value = 0.125) and ESR (p-value = 0.788) values. 9 
Table 4: Brotherton et al.. primary outcomes: increased quality of life through IBDQ and 
improved GI symptoms through pHBI.  
Table 4a: Efficacy of wheat bran diet on CD symptoms 
 Wheat Bran Group (n=4) Control Group (n=3)  
Baseline 4 wks Baseline 4 wks p-value 
IBDQ 158.3 ± 20.1 +44.25 157.7 ± 32.0 +19 0.028 
pHBI 5.3 ± 1.3 0 4.7 ± 1.5 3 0.008 
Discussion 
The primary aim of the Krebs et al. study demonstrates not only improvement of 
symptoms symptoms of CD, but also clinical remission of 80% of participants who received 
treatment. This study suggests that a natural product could provide patients with an alternative 
therapy to injectable biologics agents and specifically excluded patients already administering 
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them. A potential limitation to using a natural supplement to augment or treat any disease would 
be the safety in regulation and validity in its manufacturing. Most dietary products regulated by 
the FDA are done so differently than most food and drug products.11 The correlation between 
wormwood and the observed improvement in mood seen in HAMD scores is unclear as there is 
little evidence that wormwood may have some anti-depressant effect.7 
 Overall, the use of intervention in the Bao et al. study, provided some observable benefits 
for patients suffering from gastrointestinal symptoms secondary to CD. It is said that 
acupuncture has been utilized in Chinese internal medicine as a treatment since 100 B.C.12 This 
ancient therapy has reputation for alleviating many sub-clinical ailments and boasts little side 
effects or adverse reactions.12 As an alternative therapy in combination with partitioned 
moxibustion, this appears to be an effective treatment for this particular patient population.  
The limitations of this study were observed in the outcomes measured. Unlike the CDAI 
scores, the IBDQ and other laboratory values were only recorded post-treatment.8 The primary 
efficacy indicator, CDAI, was documented at the 12 and 24 week follow up to ascertain progress 
and stability.8 This study also did not address any mood or affective symptoms that are 
commonly associated with CD and IBD.  
As a whole, the Brotherton et al. study demonstrated ease of implementing an affordable 
and tolerable whole wheat food into daily diet, which is beneficial to a population with 
advancing need for alternatives in health care.  As a complex carbohydrate, wheat bran is 
fermentable, which allows it to provide the gut with a rich source of microbiota that would 
enhance the natural flora.9 It is also rich in fiber, which slows gastric transit time and increases 
the water-binding capacity of luminal contents, ultimately reducing the frequency of diarrhea and 
constipation associated symptoms of CD.  
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This study was limited by it’s small sample size and potentially by the duration of the 
study. There were numerous exclusion criteria, as well as an exclusively female control group. In 
the results section, the author comments on the unreliability pertaining to the secondary aim of 
this study. regarding the measurements in inflammatory markers. CRP and ESR are both non-
specific lab markers and provide little insight regarding specifics of gastrointestinal 
inflammation.9 
Conclusion 
The three studies reviewed in order to support the question, “Are CAMs safe and 
effective in improving symptoms of adult patients over the age of 18 with active Crohn disease?” 
demonstrate some evidence that CAMs may improve acute symptoms of Crohn disease and an 
increased quality of life. However, it is inconclusive whether these therapies actually provide 
long-term results in healing patients with CD. This review is ultimately limited by the use of 
different types of CAMs in each of the articles. With no identifiable harms in the above studies, 
the discussed interventions could be an alternative option to augment traditional medical 
treatment for patients suffering from this chronic and incurable disease. It would benefit future 
studies like these to observe participants over a longer period of time, as well as scheduled 
follow up visits for those who achieve early remission.  
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